| Literature DB >> 30545990 |
Robert I Haddad, Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney Goldner, Megan Haymart, Carl Hoh, Jason P Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M Lamonica, Bryan McIver, Christopher D Raeburn, John A Ridge, Matthew D Ringel, Randall P Scheri, Jatin P Shah, Rebecca Sippel, Robert C Smallridge, Cord Sturgeon, Thomas N Wang, Lori J Wirth, Richard J Wong, Alyse Johnson-Chilla, Karin G Hoffmann, Lisa A Gurski.
Abstract
The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic thyroid carcinoma.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30545990 DOI： 10.6004/jnccn.2018.0089
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908